Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis

Multiple Myeloma (MM) is a malignant disorder of plasma cells which, despite significant advances in treatment, remains incurable. Daratumumab, the first CD38 directed monoclonal antibody, has shown promising activity alone and in combination with other agents for MM treatment. Daratumumab is though...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Naicker, Serika D, Feerick, Claire L, Lynch, Kevin, Swan, Dawn, McEllistrim, Cian, Henderson, Robert, Leonard, Niamh A, Treacy, Oliver, Natoni, Alessandro, Rigalou, Athina, Cabral, Joana, Chiu, Christopher, Sasser, Kate, Ritter, Thomas, O’Dwyer, Michael, Ryan, Aideen E
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7849715/
https://ncbi.nlm.nih.gov/pubmed/33552684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1859263
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados